These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 28103444

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M, Mannucci PM.
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R.
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E, KOGENATE Bayer European PMS Study Group.
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M, Rapisarda CAP.
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [Abstract] [Full Text] [Related]

  • 17. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM, Shi Q, Bonanad S, Klamroth R.
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [Abstract] [Full Text] [Related]

  • 18. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ, Sidonio RF, O'Day K, Runken MC, Meyer K, Spears J.
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.